![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PHASE II TRIAL INITIATED FOR KOS-862
PHASE II TRIAL INITIATED FOR KOS-862
July 3, 2006
Kosan Biosciencees has begun a Phase II clinical trial to evaluate the safety and efficacy of KOS-862 (Epothilone D) as a monotherapy for prostate cancer.
KOS-862 is a polyketide that inhibits cancer cells by the same mechanism as paclitaxel. Preclinical models have shown the compound to be effective against paclitaxel-resistant tumors.
The trial design involves the intravenous administration of KOS-862 weekly for three of four weeks at a dose of 100mg/m2. The trial will enroll between 20 and 50 patients with hormone-refractory prostate cancer who have progressed after treatment with a Taxotere-based regimen. The changes in prostate specific antigen and tumor response will be assessed to determine clinical activity.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct